Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice

Virus Research

Volumn 167, Issue 2, 2012, Pages 236-246

  Khan, Mohsin ^a   Dhanwani, Rekha ^a   Rao, Putcha Venkata Lakshamana ^a   Parida, Manmohan ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Cell mediated response; Chikungunya vaccine; Cytokine profiling; Envelope protein; Humoral response

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CHIKUNGUNYA ALPHAVIRUS1 RECOMBINANT PROTEIN; CHIKUNGUNYA ALPHAVIRUS2 RECOMBINANT PROTEIN; FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN E1; GLYCOPROTEIN E2; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; RECOMBINANT PROTEIN; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VOLUME; CELLULAR IMMUNITY; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG FORMULATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SPLEEN CELL; TH1 CELL; TH2 CELL; UPREGULATION; VACCINATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHIKUNGUNYA VIRUS; CYTOKINES; HUMANS; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SPLEEN; TH1 CELLS; TH2 CELLS; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

CHIKUNGUNYA VIRUS; MUS;

EID: 84863873893     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.05.004     Document Type: Article

References (34)

1. Babu P.J., Pattnaik P., Gupta N., Shrivastava A., Khan M., Rao P.V.L. Immunogenicity of a recombinant domain III protein of dengue virus type 4 with various adjuvant in mice. Vaccine 2008, 26:4655-4663.
2. Charell R.N., Lamballrie X., Raoult D. Chikungunya outbreaks; the globalization of vector borne diseases. New England Journal of Medicine 2007, 356:769-771.
3. Couderc T., Khandoudi N., Grandadam M., Visse C., Gangneux N., Bagot S., Prost J-F., Lecuit M. Prophylaxis and therapy for chikungunya virus infection. Journal of Infectious Diseases 2009, 20:516-523.
4. Couderc T., Lecuit M. Focus on Chikungunya pathophysiology in human and animal models. Microbes and Infection 2009, 11:1197-1205.
5. Dash P.K., Parida M.M., Santhosh S.R., Verma S.K., Tripathi N.K., Ambuj S., Saxena P., Gupta N., Chaudhary M., Babu J.P., Lakshmi V., Mamidi N., Subhalaxmi M.V., Lakshmana Rao P.V., Sekhar K. East Central South African genotype as causative agent in re-emergence of Chikungunya outbreak in India. Vector Borne and Zoonotic Diseases 2007, 7:719-727.
6. Eckels K.H., Harrison V.R., Hetrick F.M. Chikungunya virus vaccine prepared by Tween-ether extraction. Applied Microbiology 1970, 19:321-325.
7. Edelman R., Ascher M.S., Oster C.N., Ramsburg H.H., Cole F.E., Eddy G.A. Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). Journal of Infectious Diseases 1979, 140:708-715.
8. Edelman R., Tacket C.O., Wasserman S.S., Bodison S.A., Aerry J.G., Mgnifica J.A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. American Journal of Tropical Medicine and Hygiene 2000, 62:681-685.
9. Enserink M. Infectious diseases. Massive outbreak draws fresh attention to little-known virus. Science 2006, 311:1085.
10. Gazzinelli R.T. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. Journal of Immunology 1996, 157:798-805.
11. Gerardin P., Barau G., Michault A., Bintner M., Randrianaivo H., Choker G., Lenglet Y., Touret Y., Bouveret A., Grivard P., Le Roux K., Blanc S., Schuffenecker I., Couderc T., Arenzana-Seisdedos F., Lecuit M., Robillard P-Y. Multidisciplinary prospective study of mother-to-child Chikungunya virus infections on the Island of La Réunion. PLoS Medicine 2008, 5:e60.
12. Gould E.A., Clegg T.C.S. Growth, assay and purification of Alphaviruses and Flaviviruses. Virology: A Practical Approach 1991, 43-78. Oxford University Press. B.W.J. Mahy (Ed.).
13. Harrison V.R., Eckels K.H., Bartellori P.J., Hampton C. Production and evaluation of a formalin-killed Chikungunya vaccine. Journal of Immunology 1971, 107:643-647.
14. Johnson R.E., Peters C.J. Alphavirus associated primarily with fever and polyarthritis. Fields Virology 1996, 843-898. Lippincott-Raven Publishers, Philadelphia. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
15. Jupp P.G., McIntosh B.M. Chikungunya virus disease. The Arboviruses: Epidemiology and Ecology 1988, 137-157. CRC Press, Boca Raton. T.P. Monath (Ed.).
16. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
17. Levitt N.H., Ramsburg H.H., Hasty S.E., Repik P.M., Cole F.E., Lupton H.W. Development of attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986, 4:157-162.
18. -ΔΔCt method. Methods 2001, 25:402-408.
19. Moore K.W., Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 2001, 19:683-765.
20. Muthumani K., Lankaraman K.M., Laddy D.J., Sundaram S.G., Chung C.W., Sako E., Wu L., Khan A., Sardesai N., Kim J.J., Vijayachari P., Weiner D.B. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 2008, 26:5128-5134.
21. Nakao E., Hotta S. Immunogenicity of purified, inactivated chikungunya virus in monkeys. Bulletin of the World Health Organization 1973, 48:559-562.
22. Powers A.M., Logue C. Changing patterns of chikungunya virus: re-emergence of zoonotic arbovirus. Journal of General Virology 2007, 88:2363-2377.
23. Ramos-Payán R., Aguilar-Medina M., Estrada-Parra S., González-Y-Merchand J.A., Favila-Castillo L., Monroy-Ostria A., Estrada-Garcia I.C. Quantification of cytokine gene expression using an economical real-time polymerase chain reaction method based on SYBR Green I. Scandinavian Journal of Immunology 2003, 57:439-445.
24. Russell P.K., Nisalak A., Sukhavachana P., Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. Journal of Immunology 1967, 99:285-290.
25. Santhosh S.R., Parida M.M., Dash P.K., Pateriya A., Pattnaik B., Pradhan H.K., Tripathi N.K., Ambuj S., Gupta N., Saxena P., Lakshmana Rao P.V. Development and evaluation of SYBR Green I based one step real time RT-PCR assay for detection and quantification of Chikungunya virus. Journal of Clinical Virology 2007, 39:188-193.
26. Santhosh S.R., Dash P.K., Parida M.M., Khan M., Tiwari M., Rao P.V.L. Comparative full genome analysis revealed A226V shift in 2007 Indian Chikungunya virus isolates. Virus Research 2008, 135:36-41.
27. Schuffenecker I., Iteman I., Michault A., Murri S., Frangeul L., Vaney M., Lavenir R., Pardigon N., Reynes J.M., Francois P., Leon B., Diancourt L., Michel S., Duquerroy S., Guigan G., Frankiel M., Brehin A., Cubito N., Despres P., Kunst F., Rey F.A., Zeller H., Brisse S. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Medicine 2006, 3:e263.
28. Shukla J., Bhargava R., Dash P.K., Parida M., Tripathi N., Rao P.V.L. Cloning and expression of domain III of the envelope gene of Japanese encephalitis virus: evaluation for early diagnosis by IgM ELISA. Journal of Virological Methods 2009, 158:165-170.
29. Strauss J.H., Strauss E.G. The Alphaviruses: gene expression, replication and evolution. Microbiological Reviews 1994, 58:491-562.
30. Strauss J.H., Strauss E.G. Recombination in alphaviruses. Seminars in Virology 1997, 8:85-94.
31. Tiwari M., Parida M.M., Santosh S.R., Khan M., Dash P.K., Rao P.V.L. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009, 27:2513-2522.
32. Tsetsarkin K.A., Vanlandingham D.L., McGee C.E., Higg S. A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PloS Pathogen 2007, 3:1-12.
33. Wang E., Volkova E., Adams A.P., Forrester N., Xiao S.Y., Frolov I., Weaver S.C. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008, 26:5030-5039.
34. Ziegler S.A., Lu L., Travassos da Rosa A.P.A., Xiao S.Y., Tesh R.B. An animal model for studying the pathogenesis of Chikungunya virus infection. American Journal of Tropical Medicine and Hygiene 2008, 79:133-139.